<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Gan & Lee Pharmaceuticals Co., Ltd. Class A — News on 6ix</title>
<link>https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd</link>
<description>Latest news and press releases for Gan & Lee Pharmaceuticals Co., Ltd. Class A on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/gan-and-lee-pharmaceuticals-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683642d378dffbe2df14fd50.webp</url>
<title>Gan & Lee Pharmaceuticals Co., Ltd. Class A</title>
<link>https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd</link>
</image>
<item>
<title>Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide</title>
<link>https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-and-lee-pharmaceuticals-signs-exclusive-license-agreement-with-jw-pharmaceutical-the-leading-south-korean-pharma-to-advance-the-global-commercialization-of-the-innovative-glp-1-receptor-agonist-bofanglutide</link>
<guid isPermaLink="true">https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-and-lee-pharmaceuticals-signs-exclusive-license-agreement-with-jw-pharmaceutical-the-leading-south-korean-pharma-to-advance-the-global-commercialization-of-the-innovative-glp-1-receptor-agonist-bofanglutide</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and develope</description>
</item>
<item>
<title>Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2</title>
<link>https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-and-lee-pharmaceuticals-once-weekly-basal-insulin-gzr4-injection-meets-primary-endpoints-in-two-pivotal-phase-3-clinical-trials-super-1-and-super-2</link>
<guid isPermaLink="true">https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-and-lee-pharmaceuticals-once-weekly-basal-insulin-gzr4-injection-meets-primary-endpoints-in-two-pivotal-phase-3-clinical-trials-super-1-and-super-2</guid>
<pubDate>Tue, 31 Mar 2026 13:50:00 GMT</pubDate>
<description>Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection, have successfully met their pre-specified primary endpoints. After 26 weeks of treatment, once-weekly GZR4 demonstrated statistically significant superior efficacy in reducing glycated hemoglobin A1c (HbA1c)* compared with once-daily insulin glargine U100 (Lantus®) and once-daily insulin degludec (Tresiba®).</description>
</item>
<item>
<title>Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management</title>
<link>https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/once-monthly-glp-1-ra-085700223</link>
<guid isPermaLink="true">https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/once-monthly-glp-1-ra-085700223</guid>
<pubDate>Thu, 27 Nov 2025 08:57:00 GMT</pubDate>
<description>Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adults with obesity or overweight. In this study, bofanglutide injection will be administered subcutaneously once every four weeks (once-monthly) to explore its potential to maintain the achieved weight loss and improved long-term adherence.</description>
</item>
<item>
<title>Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions</title>
<link>https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-lee-pharmaceuticals-presented-multiple-110600094</link>
<guid isPermaLink="true">https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-lee-pharmaceuticals-presented-multiple-110600094</guid>
<pubDate>Sat, 21 Jun 2025 11:06:00 GMT</pubDate>
<description>Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions.</description>
</item>
<item>
<title>Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity</title>
<link>https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-lee-pharmaceuticals-announced-first-154500670</link>
<guid isPermaLink="true">https://6ix.com/company/gan-and-lee-pharmaceuticals-co-ltd/news/gan-lee-pharmaceuticals-announced-first-154500670</guid>
<pubDate>Mon, 10 Mar 2025 15:45:00 GMT</pubDate>
<description>Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide (research code: GZR18) injection, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently developed by Gan & Lee, in the US participants with overweight or obesity. Notably, bofanglutide is the first GLP-1 receptor mono-agonist to undergo a head-to-head comparison with tirzepatide for evaluating t</description>
</item>
</channel>
</rss>